Alkermes plc (NASDAQ:ALKS) is one of the stocks Jim Cramer recently looked at. When a caller asked Cramer about the stock, he said: Okay… by this point, something should have happened, much better there than it has. I do not recommend the stock. I think it’s a hold, maybe a weak one. Photo by Joshua Mayo on Unsplash Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company that develops and sells medicines to treat schizophrenia, bipolar I disorder, and addiction to alcohol or opioids. On January 6, t ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Alkermes (ALKS) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 21.75%.For the last reported quar ...

Group 1: Guess, Inc. (GES) - Guess, Inc. is a lifestyle and apparel company with a Zacks Rank of 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 5.6% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 9.93, significantly lower than the industry average of 24.40 [1] - Guess possesses a Value Score of B [1] Group 2: National Energy Services Reunited Corp. (NESR) - National Energy Services Reunited Corp. is an oilfield services company with a Zacks Rank of 1 [2] - The Zacks Consensus Estimate for its next year earnings has increased by 4.1% over the last 60 days [2] - The company has a price-to-earnings ratio (P/E) of 11.85, compared to the industry average of 21.60 [2] - NESR possesses a Value Score of A [2] Group 3: Alkermes plc (ALKS) - Alkermes plc is a biopharmaceutical company with a Zacks Rank of 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 3.1% over the last 60 days [3] - The company has a price-to-earnings ratio (P/E) of 19.23, lower than the S&P average of 25.72 [3] - Alkermes possesses a Value Score of A [3]

Core Insights - Alkermes is positioned for growth in 2026, building on accomplishments from 2025 to enhance its value creation potential [3][5] - The company is characterized as a profitable neuroscience firm with a late-stage candidate, indicating a strong foundation for future development [5] Company Overview - Alkermes is participating in the 44th Annual Healthcare Conference, showcasing its management team and strategic direction [2] - The CEO, Richard Pops, expressed excitement about the company's trajectory and future opportunities [3] Financial and Strategic Position - The company emphasizes its strong foundation for both near-term and long-term growth, highlighting its profitability and leadership in the neuroscience sector [5]

Alkermes Conference Call Summary Company Overview - **Company**: Alkermes - **Industry**: Biotechnology, specifically in neuroscience and sleep medicine - **Key Products**: ALKS 2680 (orexin compound), Vivitrol, Lybalvi, Aristada, Lumryz Core Points and Arguments Financial Performance - In 2025, Alkermes' commercial business generated over **$1.4 billion** in total revenues, demonstrating strong cash flow and profitability [3] - The planned acquisition of Avidel and its product Lumryz is expected to enhance revenue growth and diversify the commercial portfolio [26] Product Development - **ALKS 2680** is entering phase three trials for narcolepsy, following a successful phase two program [3][9] - The drug has been granted **FDA Breakthrough Therapy designation** for narcolepsy type 1 (NT1) [4][30] - The market opportunity for ALKS 2680 in narcolepsy and idiopathic hypersomnia (IH) is projected to exceed **$10 billion annually** [6][8] Market Dynamics - There are approximately **200,000** people in the U.S. with narcolepsy, with only about half diagnosed [6] - Currently, **80,000** patients are receiving treatment for narcolepsy, but **80%** report residual symptoms [7] - The branded pharmaceutical market for narcolepsy treatments, particularly oxybates, is limited, with only **16,000 to 18,000** patients using them annually [8] Clinical Trials and Efficacy - The Vibrance studies demonstrated statistically significant improvements in sleep latency and excessive daytime sleepiness for ALKS 2680 [11] - Approximately **95%** of patients in the studies opted to continue into the safety extension phase, indicating high patient satisfaction [12] - The ongoing phase two study for IH is expected to complete in Q4 2026, with plans to initiate the phase three program shortly after the end-of-phase two meeting with the FDA [15][17] Future Growth and Pipeline - Alkermes plans to develop additional compounds, including **ALK-7290** for ADHD and **ALK-4510** for fatigue associated with neurodegenerative diseases [20][23] - The company aims to leverage its experience in drug development to establish a strong presence in the ADHD market, which includes approximately **15.5 million** adults and **6.5 million** children diagnosed with the condition [22] Competitive Positioning - ALKS 2680 is positioned to compete effectively against Takeda's product due to its broader therapeutic index and multiple dosing options [43][44] - The company emphasizes the importance of rigorous clinical data to create barriers for future competitors [46][47] Additional Important Insights - The acquisition of Avidel is expected to close soon, enhancing Alkermes' entry into the sleep medicine market [10][27] - The company has a strong financial foundation, with over **$1.3 billion** in net sales from its existing products [27] - Alkermes is focused on addressing unmet patient needs in narcolepsy and other sleep disorders, emphasizing the importance of patient-reported outcomes in clinical trials [50][51] This summary encapsulates the key points discussed during the conference call, highlighting Alkermes' strategic direction, product pipeline, and market opportunities.

Financial Performance & Acquisition - Alkermes' commercial business generated revenues exceeding $1.45 billion in 2025, demonstrating strong cash flow and profitability[5] - The planned acquisition of Avadel is expected to augment revenue growth and enhance profitability in 2026[5, 46] - LUMRYZ has generated over $390 million in net revenues since its launch as of September 30, 2025[49] Alixorexton Development Program - Alixorexton has blockbuster potential in narcolepsy and idiopathic hypersomnia and was granted FDA Breakthrough Therapy designation in NT1, with Phase 3 initiation planned for Q1 2026[5] - Phase 2 Vibrance-1 study showed statistically significant improvements in mean sleep latency and excessive daytime sleepiness, with clinically meaningful improvements in weekly cataplexy rates in NT1 patients[16] - Phase 2 Vibrance-2 study demonstrated clinically meaningful improvements in wakefulness and excessive daytime sleepiness in NT2 patients[19] Market Opportunity & Pipeline Expansion - The orexin 2 receptor agonist class represents a potential multi-billion dollar market opportunity in narcolepsy and idiopathic hypersomnia[9] - The oxybate market for narcolepsy and idiopathic hypersomnia generated over $1.8 billion in revenues in 2024[11] - Approximately 80,000 narcolepsy patients are treated, with 80% reporting residual symptoms[11] - Alkermes is planning a Phase 2 study of ALKS 4510 in 2026 for fatigue associated with multiple sclerosis and Parkinson's Disease, with a prevalence of approximately 1 million patients each in the US[40]

Revenue Estimates - Alkermes plc will present its estimated total revenues for the year ended December 31, 2025, during the J.P. Morgan Healthcare Conference on January 13, 2026[5] - The revenue figures are preliminary, unaudited, and subject to change upon completion of the financial statement review for the year ended December 31, 2025[5] - A corporate presentation detailing these estimates has been made available as Exhibit 99.1[5]

Core Insights - The pharmaceutical industry is experiencing a significant shift in sentiment as executives prepare for the upcoming J.P. Morgan Healthcare Conference, with a more relaxed attitude compared to 2025 [1] - Concerns regarding drug pricing policies and tariffs that could erode profits have largely dissipated, leading to a notable reduction in industry anxiety [1][3] - Biopharmaceutical transactions have more than doubled over the past year, with expectations for continued growth in 2026 [1][3] Group 1 - The J.P. Morgan Healthcare Conference serves as a key networking and deal-making event for thousands of biopharmaceutical executives and investors [3] - A recent agreement with the White House aimed at lowering drug prices has positively influenced market sentiment, as companies have not significantly adjusted their financial outlooks [3] - In 2025, pharmaceutical companies completed $130 billion in transactions, a 124% increase from the previous year, with approximately 30 deals exceeding $1 billion [3] Group 2 - Major pharmaceutical companies like Merck, Pfizer, and Bristol-Myers Squibb are under pressure to replenish their product pipelines as blockbuster drug patents expire in the next five years, threatening over $300 billion in sales [6] - The rising stock prices have emboldened CEOs to pursue mergers and acquisitions, leading to competitive bidding wars for biotech firms developing potential blockbuster drugs [6][7] - Mid-sized companies are also actively acquiring early-stage biotech firms, indicating a shift in strategy as they seek growth opportunities [7] Group 3 - Despite the optimism, rising valuations may deter potential buyers from pursuing acquisitions [7] - Political uncertainties remain, particularly with the Trump administration's influence on the FDA and its unpredictable leadership changes [8] - The FDA has recently rejected several rare disease drug applications, causing frustration among investors and advocacy groups, which may lead to a more cautious approach to major mergers [8]

Alkermes plc (NASDAQ: ALKS) is advancing in the neuroscience and oncology sectors, with significant developments in sleep medicine.Executive VP Craig C. Hopkinson sold 5,000 shares, remaining with 61,740 shares, amidst the company's financial growth highlighted by a 32% increase in Lybalvi sales.The company's stock price reflects a modest increase, supported by a strong market capitalization and trading volume, alongside promising clinical trial results for Alixorexton.Alkermes plc (NASDAQ: ALKS) is a bioph ...

Core Viewpoint - The bullish thesis on Alkermes (ALKS) is grounded in the evaluation of synergies from the recent Vibrance-2 clinical trial results, rather than mere speculation about future outcomes [1] Group 1: Company Analysis - Alkermes is positioned in a high-growth sector, focusing on disruptive technologies and innovative enterprises [1] - The analysis emphasizes a combination of fundamental analysis and future trend predictions to identify potential investment opportunities [1] Group 2: Industry Insights - The company operates in sectors that are expected to experience exponential expansion, highlighting the importance of innovation for substantial returns [1]